PRESIDENT HAS SERVED AS A REVIEWER FOR THE ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the ZRG1 BST-H (50) PAR-16-390 ‘NIBIB Trailblazer Award for New and Early Stage Investigators’ (R21) Study Section for the National Institute of Health (NIH) held on June 28, 2017.

pdx news

  • PDX PHARMA RECEIVED A PERFECT SCORE (10) ON ITS FAST-TRACK NCI-SBIR GRANT APPLICATION AND FUNDABLE SCORE (18) ON ITS PHASE II APPLICATION (TOTAL BUDGET OF $4.4M)

    7/1/2021
    read more

  • DATA ON AIRISE-02 PUBLISHED IN ADVANCED MATERIALS (IF 30.8)

    6/12/2021
    read more


  • PDX Pharma received the USPTO’s Notice of Allowance for the patent application on its core nanoparticle technology (Pdx-NP)

    5/6/2021
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved